1,3-β-D-Glucan in Patients Receiving Intravenous Amoxicillin–Clavulanic Acid

Abstract

To the Editor: The fungal component 1,3-β-D-glucan is increasingly used to diagnose opportunistic invasive mycoses in immunocompromised patients.1–3 The 1,3-β-D-glucan assay (Fungitell, Associates of Cape Cod) was recently approved by the Food and Drug Administration. We found that the serum samples from two patients with hematologic conditions were positive for 1,3-β-D-glucan during treatment with intravenous amoxicillin–clavulanic acid. Serum samples were negative after treatment was discontinued. Neither patient had evidence of invasive fungal disease. Furthermore, 1,3-β-D-glucan was detected in the amoxicillin–clavulanic acid used to treat these patients. We then tested 10 serum samples from six patients treated with intravenous amoxicillin–clavulanic . . .